Back
Speaker illustration

undefined undefined undefined

Presentations

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.

Event: Heart Failure 2025

Topic: Cardio-Oncology

Session: Interventions to improve outcomes in cardio-oncology

Access
Like
Thumbnail

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Event: ESC Congress 2024

Topic: Antidiabetic Pharmacotherapy

Session: Real-world evidence on the cardiovascular effects of therapies for diabetes

Access
Like
Thumbnail

The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

Event: ESC Congress 2023

Topic: Cardio-Oncology

Session: Cardiotoxicity: mechanisms, biomarkers, and treatment

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources